ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Agilvax, Inc., a biotechnology company developing targeted antibody-based therapeutics for the treatment of various types of cancers announced today that Joseph Patti, Ph.D., will join its Board of Directors as Executive Chairman. Dr. Patti has over two decades of drug development experience in the biopharmaceutical industry and has

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today reported that eight abstracts–including two oral presentations–on the Company’s lead product candidate rivo-cel (formerly BPX-501), in addition to an abstract on its controllable CAR program, were accepted for presentation at the 60th American

Four Houston high-achievers earned top honors as the 2019 Women in Science with Excellence (WISE) honorees, BioHouston announced today. The award recognizes women in science-related roles who have made significant contributions in science, technology, engineering or mathematics.